Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2⁺ Breast Cancer Cells.

ABSTRACT: Cancers overexpressing the ERBB2 oncogene are aggressive and associated with a poor prognosis. Trastuzumab is an ERBB2 specific recombinant antibody employed for the treatment of these diseases since it blocks ERBB2 signaling causing growth arrest and survival inhibition. While the effects of Trastuzumab on ERBB2 cancer cells are well known, those on the extracellular vesicles (EVs) released from these cells are scarce. This study focused on ERBB2⁺ breast cancer cells and aimed to establish what type of EVs they release and whether Trastuzumab affects their morphology and molecular composition. To these aims, we performed immunoelectron microscopy, immunoblot, and high-resolution mass spectrometry analyses on EVs purified by differential centrifugation of culture supernatant. He

SUBMITTER: Marconi S 

PROVIDER: S-EPMC8000509 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature